QC
DMAC icon

Quadrature Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Quadrature Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Sell
22,039
-1,533
-7% -$12.1K ﹤0.01% 1173
2025
Q4 		$188K Buy
+23,572
New +$176K ﹤0.01% 989

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quadrature Capital's DMAC Position: Q1 2026 in Review

Quadrature Capital reduced its DiaMedica Therapeutics (DMAC) stake by 6.5% in Q1 2026, selling an estimated $12.1K and leaving 22,039 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #1173.

Quadrature Capital first reported a position in DMAC in Q4 2025 and has held it in 2 quarters since. The position peaked at $188K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Quadrature Capital held 22,039 shares of DiaMedica Therapeutics worth $149K as of Q1 2026.
  • Quadrature Capital sold 1,533 DiaMedica Therapeutics shares in Q1 2026, an estimated $12.1K.
  • DiaMedica Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1173 holding.
  • Quadrature Capital first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's DiaMedica Therapeutics position peaked at $188K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.